Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in the tyrosine kinase inhibitor era

Abstract

 We retrospectively analyzed the outcomes of 14 patients with chronic myeloid leukemia (CML) who underwent allogeneic hematopoietic stem cell transplantation in the tyrosine kinase inhibitor (TKI) era. The median age of the patients was 42 years (range, 20-66 years). Disease status at transplantation was as follows: first chronic phase (CP1; n=3), second chronic phase (CP2; n=8), and accelerated phase/blast phase (AP/BP; n=3). Sources of stem cells were as follows: related bone marrow (BM; n=2), related peripheral blood stem cells (n=1), unrelated BM (n=4), and cord blood (n=7). The 3-year overall survival (OS) rate was 71%. According to the disease status at the time of transplantation, the 3-year OS rate was 67% in CP1, 75% in CP2, and 67% in AP/BP (P=0.925). The six patients newly diagnosed with BP CML achieved CP2, and the 3-year OS rate was 83%. In the TKI era, patients newly diagnosed with BP CML are expected to demonstrate improved prognosis.